Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes : Episode 13
Patient Factors Considered when Choosing Treatment Selection
Dr. Garon explains his approach to choosing between different ALK inhibitors for ALK+ NSCLC, outlining the factors that guide his selection and when he might prefer alectinib, lorlatinib, or brigatinib.
This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.
- Dr.Thawani asks Dr Garon:How do you approach choosing between the different ALK inhibitors available?
- What factors guide your selection, and in which cases might you prefer alectinib, lorlatinib, or brigatinib?
Recent Videos
